Effects of recombinant human granulocyte/macrophage colony-stimulating factor on diabetic lower extremity ulcers: Case series of nine patients

April 28, 2026

Effects of recombinant human granulocyte/macrophage colony-stimulating factor on diabetic lower extremity ulcers: Case series of nine patients


SALDY YUSUF

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 17, 2105–2106

The study introduces Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor (rhGM-CSF) to confirm its effects in clinical practice among of nine DFU cases. Despite the authors reporting that 7 out of 9 ulcers had wound size reduction to zero (0 cmΒ²) by day 18, one by day 21, and another by day 24, we note some method-related issues need to be clarified to make it possible to be replicated by other researchers.

First, the authors refer neuropathy to the Carrington Study, as a reduced nerve conduction velocity confirmed by electromyogram and abnormalities in pinprick, vibration perception, pressure perception, and temperature perception.2 The neuropathy data is presented in Table 1 as nominal data (+ or -) but fails to inform which test the authors perform and the diagnostic criteria to confirm neuropathy. We would like to highlight that currently, The International Working Group on..

Continue Reading..

DOI: 10.2147/DMSO.S478219